NL-OMON47183已完成3 期
A Phase 3, open-label, randomized, multi-center, controlled trial to evaluate the pharmacokinetics and pharmacodynamics of edoxaban and to compare the efficacy and safety of edoxaban with standard of care anticoagulant therapy in pediatric subjects from birth to less than 18 years of age with confirmed venous thromboembolism (VTE) - The Edoxaban Hokusai VTE PEDIATRICS Study
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 至 17（—）
入选标准
- •Subjects must satisfy all of the following criteria to be included in the study:
- •1. Male or female pediatric subjects between birth (defined as 38 weeks gestational age) and less than 18 years of age at the time of consent.
- •2. Pediatric subjects with the presence of documented VTE confirmed by appropriate diagnostic imaging and requiring anticoagulant therapy for at least 90 days.
- •3. Subjects must have received at least 5 days of heparin (LMWH or SP Xa inhibitors or UFH according to the edoxaban label for VTE treatment) therapy prior to randomization to treat the newly identified index VTE.
- •In addition, prior to being randomized to edoxaban or SOC, subjects initially treated with VKA are
- •recommended to have an INR < 2.0.
- •4. Subject and/or parent(s)/legal guardian(s) or legally acceptable representative is informed and provides signed consent for the child to participate in the study with edoxaban treatment. Pediatric subjects with appropriate intellectual maturity will be required to sign an assent form
- •in addition to the signed informed consent from the parent(s)/legal guardian(s) or any legally acceptable representative.
- •5. Female subjects who have menarche must test negative for pregnancy at Screening and must consent to avoid becoming pregnant by using an approved contraception method throughout the study.
排除标准
- •Subjects who meet any of the following criteria will be disqualified from entering the study:
- •1. Subjects with active bleeding or high risk of bleeding contraindicating treatment with LMWH, SP Xa inhibitors, VKAs, or direct oral anticoagulants (DOACs; identified high risk of bleeding during prior experimental administration of DOACs).
- •2. Subjects who have been or are being treated with thrombolytic agents, thrombectomy or insertion of a caval filter for the newly identified index VTE.
- •3. Administration of antiplatelet therapy is contraindicated in both arms except for low dose aspirin defined as 1-5 mg/Kg/day with maximum of 100 mg/day.
- •4. Administration of rifampin is prohibited during the study and subjects on concomitant use of rifampin are excluded.
- •5. Subjects with hepatic disease associated with coagulopathy leading to a clinically relevant bleeding risk (aPTT > 50 seconds or international normalized ratio [INR] > 2.0 not related to anticoagulation therapy) or ALT > 5 × the upper limit of normal (ULN) or total bilirubin > 2 × ULN with direct bilirubin > 20% of the total at Screening Visit.
- •6. Subjects with glomerular filtration rate (GFR) < 30% of normal for age and size.
- •7. Subjects with stage 2 hypertension defined as blood pressure (BP) systolic and/or diastolic confirmed > 99th percentile + 5 mmHg.
- •8. Subject with thrombocytopenia < 50 × 109/L at Screening Visit.
- •Subjects with a history of heparin-induced thrombocytopenia may be enrolled in the study at the Investigator's discretion.
- •9. Life expectancy less than the expected study treatment duration (3 months).
- •10. Subjects who are known to be pregnant or breastfeeding.
- •11. Subjects with any condition that, as judged by the Investigator, would place the subject at increased risk of harm if he/she participated in the study including contraindicated medications identified in Appendix 17.4.
- •12. Subjects who participated in another clinical study or were treated with an experimental therapy with less than a 30-day washout period prior to identifying the qualifying index VTE.
研究者
相似试验
未知
3 期
A phase 3 comparative study of TAP-144-SR(6M) in prostate cancer patients previously treated with hormonal therapyProstate cancerJPRN-jRCT2080221721TAKEDA PHARMACEUTICAL COMPANY LTD.160
进行中（未招募）
1 期
Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin in combination with chemotherapy.EUCTR2018-000624-33-BEHOVON Foundation768
进行中（未招募）
1 期
Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin in combination with chemotherapy.Previously untreated Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutationsMedDRA version: 20.0Level: LLTClassification code 10001941Term: AMLSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10068361Term: MDSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000624-33-LTHOVON Foundation768
进行中（未招募）
1 期
Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin in combination with chemotherapy.EUCTR2018-000624-33-ATHOVON Foundation768
已完成
3 期
A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapyAMLMDS-EB210024324Acute myeloid leukemiaNL-OMON54682HOVO250